Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation

This Phase Ib/III study evaluates the efficacy and safety of IBI351 in combination with chemotherapy in advanced non-squamous NSCLC with KRAS G12C mutation.

Trial Details

NCT ID

NCT05504278

Phase

PHASE1

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

IBI351
Cetuximab
pemetrexed
Carboplatin
Sintilimab
cis-platinum

Locations (sample)

Jilin City, Changchun, China|43.84652,126.5608

Key Eligibility Criteria

Histologically confirmed diagnosis of nonsquamous NSCLC with KRAS G12C mutation
Unresectable or metastatic disease
Adequate organ function
Not received any systemic antitumor therapy for locally advanced or metastatic non-squamous NSCLC previously.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →